Scarica l'app Stockscreener
3.0335
32.97%
0.7435
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$2.29
Aprire:
$2.45
Volume 24 ore:
4.84M
Relative Volume:
1.95
Capitalizzazione di mercato:
$253.82M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-1.0533
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+20.36%
1M Prestazione:
+5.73%
6M Prestazione:
+147.56%
1 anno Prestazione:
-23.68%
Intervallo 1D:
$2.44
$3.10
Intervallo di 1 settimana:
$2.07
$3.10
Portata 52W:
$0.9101
$4.19
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Confronta EDIT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.032 | 184.17M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.12 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.50 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.02 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.90 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
303.40 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Downgrade | Stifel | Buy → Hold |
| 2024-12-13 | Downgrade | Truist | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈
Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com UK
Editas: Q2 Earnings Snapshot - New Haven Register
Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest
Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest
Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize
Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada
Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener
Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest
Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire
Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by XTX Topco Ltd - MarketBeat
Published on: 2025-08-09 06:19:25 - Newser
Quantitative breakdown of Editas Medicine Inc. recent moveInvestment Timeline and ROI Summary Report - Newser
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $4.70 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) EVP Linda Burkly Sells 5,121 Shares - MarketBeat
What makes Editas Medicine Inc. stock price move sharplyExit Strategy Guide With Risk Control Plan - Newser
Editas Medicine SVP Parison Amy Sells 679 Shares at $2.58/Share. - AInvest
Evaluating Editas Medicine Inc. with trendline analysisAI Stock Movement Forecast with Accuracy - Newser
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceAI Entry Timing Prediction for Swing Traders - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Bank of New York Mellon Corp - Defense World
Can you recover from losses in Editas Medicine Inc.Free Early Breakout Entry Point Notifications - Newser
Editas Medicine EVP Sells Shares to Meet Tax Obligations - TradingView
Trendlines Converge — Decision Point for Editas Medicine Inc.Real Profit Trade Plan Suggestions Shared Widely - beatles.ru
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why is Editas Medicine Inc. stock attracting strong analyst attentionAccess powerful market insights for free - Jammu Links News
How strong is Editas Medicine Inc. company’s balance sheetConsistently superior profits - Jammu Links News
What are analysts’ price targets for Editas Medicine Inc. in the next 12 monthsUnlock powerful trading alerts for success - Jammu Links News
When is Editas Medicine Inc. stock expected to show significant growthGet alerts on top growth stocks daily - Jammu Links News
What institutional investors are buying Editas Medicine Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Should I hold or sell Editas Medicine Inc. stock in 2025Maximize your portfolio’s earning power - Jammu Links News
Is Editas Medicine Inc. a growth stock or a value stockHigh-profit stock alerts - Jammu Links News
Cwm LLC Has $55,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
What is Editas Medicine Inc. company’s growth strategyTriple-digit profit margins - Jammu Links News
What are the technical indicators suggesting about Editas Medicine Inc.Invest smarter with actionable trading signals - Jammu Links News
Is Editas Medicine Inc. stock overvalued or undervaluedAchieve consistent double-digit growth rates - Jammu Links News
What catalysts could drive Editas Medicine Inc. stock higher in 2025High-yield trading alerts - Jammu Links News
Editas Medicine Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
What are the key drivers behind the recent increase in EDIT's trading volume? - AInvest
What is the dividend policy of Editas Medicine Inc. stockTop Growth Alerts With Proven Results - Jammu Links News
Editas Medicine Outperforms Medical Sector This Year Despite Zacks Rank #2 - AInvest
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? - Yahoo Finance
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):